Data Insights

Annamycin by Moleculin Biotech for Synovial Sarcoma: Likelihood of Approval

Annamycin is under clinical development by Moleculin Biotech and currently in Phase II for Synovial Sarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Annamycin in Synovial Sarcoma

Data Insights

Annamycin by Moleculin Biotech for Liposarcoma: Likelihood of Approval

Annamycin is under clinical development by Moleculin Biotech and currently in Phase II for Liposarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Annamycin in Liposarcoma

Data Insights

Annamycin by Moleculin Biotech for Angiosarcoma: Likelihood of Approval

Annamycin is under clinical development by Moleculin Biotech and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Annamycin in Angiosarcoma

Data Insights

Annamycin by Moleculin Biotech for Soft Tissue Sarcoma: Likelihood of Approval

Annamycin is under clinical development by Moleculin Biotech and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Annamycin in Soft Tissue Sarcoma

Data Insights

Annamycin by Moleculin Biotech for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Annamycin is under clinical development by Moleculin Biotech and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Annamycin in Refractory Acute Myeloid Leukemia

Data Insights

Annamycin by Moleculin Biotech for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Annamycin is under clinical development by Moleculin Biotech and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Annamycin in Relapsed Acute Myeloid Leukemia